Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-25T18:01:37.140Z Has data issue: false hasContentIssue false

Pharmacologic Treatment of Epilepsy

Published online by Cambridge University Press:  07 November 2014

Extract

A 64-year-old man had a first generalized seizure. He was seen in an emergency room where magnetic resonance imaging revealed a right parietal meningioma with a diameter of 2.5 cm. He was seen by the neurosurgery team and a craniotomy was performed. He was discharged from the hospital on phenytoin. Three weeks later he reported drowsiness and unsteadiness to his neurologist. In addition, he described episodes of transient sensory disturbance in his left arm, sometimes with twitching movements of the left hand and wrist. These episodes could last ≤3 minutes, and his hand and arm would be weak afterward for several hours. A phenytoin level was measured at 17. Lamotrigine was added to his regimen, and on 400 mg/day the lamotrigine level was 3.8. The dose was increased gradually to 400 mg BID and seizures stopped. Two hours after each dose, however, the patient would become dizzy, nauseated, and encephalopathic for a period of 60–90 minutes.

The patient presented with a convulsive seizure due to a meningioma and developed simple partial sensorymotor seizures arising in the region of the meningioma after its resection. The seizures persisted with phenytoin at a moderately high serum level but responded to lamotrigine as a second agent at just above the maximum tolerated dose. This case illustrates a common course of events for otherwise healthy adults who have seizures due to structural brain disease and are placed on phenytoin and lamotrigine.

Type
Research Article
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Brodie, MJ, Overstall, PW, Giorgi, L. Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res. 1999:37:8187.CrossRefGoogle ScholarPubMed
2.Rowan, AJ, Ramsay, RE. Collins, JF, et al.New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:18681873.CrossRefGoogle ScholarPubMed
3.Jannuzzi, G, Cian, P, Fattore, C, et al.A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia. 2000:41(2):222230.CrossRefGoogle Scholar
4.Larkin, JG, Herrick, AL, McGuire, GM, Percy-Robb, IW, Brodie, MJ. Antiepileptic drug monitoring at the epilepsy clinic: a prospective evaluation. Epilepsia. 1991:32(1):8995.CrossRefGoogle ScholarPubMed
5.Johannessen, SI. Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs. Ther Drug Monit. 2005;27(6):710713.CrossRefGoogle ScholarPubMed
6.Tompson, DJ, Ali, I, Oliver-Willwong, R.et al.Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia. 2008;49(3):410417.CrossRefGoogle ScholarPubMed
7.Ramsay, RE, Uthman, B, Pryor, FM, et al.Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia. 2008;49(7):11801185.CrossRefGoogle ScholarPubMed
8.Fakhoury, TA, Miller, JM, Hammer, AE, Vuong, A. Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study. Drugs Aging. 2008;25(11):955962.CrossRefGoogle ScholarPubMed
9.Gadde, KM, Franciscy, DM, Wagner, HR 2nd, Krishnan, KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003, 289(14):18201825.CrossRefGoogle ScholarPubMed
10.Kutlu, G, Gomceli, YB, Unal, Y, Inan, LE. Levetiracetam monotherapy for late poststroke seizures in the elderly. Epilepsy Behav. 2008:13(3):542544.CrossRefGoogle ScholarPubMed
11.Dogan, EA, Usta, BE, Bilgen, R, Senol, Y, Aktekin, B. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav. 2008:13(1):156161.CrossRefGoogle ScholarPubMed
12.Mattson, RH, Cramer, JA, Collins, JF, et al.Comparison of carbamazepine, phenobarbital. phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985:313(3):145151.CrossRefGoogle ScholarPubMed
13.Marson, AG, Al-Kharusi, AM, Alwaidh, M, et al.The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):10001015.CrossRefGoogle ScholarPubMed
14.Marson, AG, Al-Kharusi, AM, Alwaidh, M, et al.The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):10161026.CrossRefGoogle ScholarPubMed